Allergy Therapeutics plc provided revenue guidance for the six months ended 31 December 2016. The company expected revenue to be £40.4 million against £29.0 million, representing 17.9% organic growth at constant currency (39.3% growth on a reported basis, aided by the impact on euro revenues of the weak pound). This growth reflects continued strong momentum across the majority of the company's key markets.